Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

5.75SEK
24 Mar 2017
Change (% chg)

0.15kr (+2.68%)
Prev Close
5.60kr
Open
5.50kr
Day's High
5.75kr
Day's Low
5.50kr
Volume
10,528
Avg. Vol
23,828
52-wk High
9.75kr
52-wk Low
5.25kr

Latest Key Developments (Source: Significant Developments)

Karolinska Development: research collaboration with Memorial Sloan Kettering Cancer Center
Wednesday, 22 Mar 2017 08:00am EDT 

Karolinska Development AB : Karolinska Development company Aprea Therapeutics announces research collaboration with Memorial Sloan Kettering Cancer Center .Announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246.  Full Article

Karolinska Development: Modus Therapeutics raises SEK 32 mln
Monday, 20 Feb 2017 02:37am EST 

Karolinska Development AB : Karolinska Development company Modus Therapeutics raises 32 million Swedish crowns ($3.5 million)to support development of sevuparin for sickle cell disease .Top-line data from this phase II study is expected in H1 2018.  Full Article

Karolinska Development offers set-off share issue to convertible holders
Tuesday, 7 Feb 2017 01:18am EST 

Karolinska Development AB : Said on Monday will present a proposal to shareholders to approve its decision on a new issue of B-shares to the convertible holders offering the convertible holders to "set-off" their convertibles as payment for new B-shares .Concluded that reducing the convertible debt will lead to a strengthening of the company's equity position and ensuring that its current cash resources can be used to invest in new portfolio companies.  Full Article

Karolinska Development: OssDsign announces new European partnerships
Thursday, 12 Jan 2017 02:00am EST 

Karolinska Development AB : Its portfolio company OssDsign AB announces new European partnerships for commercialization of novel medical implants .OssDsign has entered new commercial partnerships covering distribution of its products in Italy, Spain, Switzerland, Austria and Netherlands.  Full Article

Karolinska Development's Dilafor raises SEK 51 million for study
Tuesday, 27 Sep 2016 02:00am EDT 

Karolinska Development Ab : Karolinska Development portfolio company Dilafor AB raises 51 million Swedish crowns ($6 million) to facilitate phase IIb clinical study with tafoxiparin . Financing has no impact on Karolinska Development's fair value . As a result of new financing, Karolinska Development has decreased its indirect holdings via KDev investments in Dilafor from 53% to 35% .Successful completion of financing round enables Dilafor to facilitate a phase IIb dose finding trial with tafoxiparin trial in northern europe.  Full Article

Karolinska Development Q2 net sales fall to SEK 0.6 mln
Wednesday, 31 Aug 2016 02:42am EDT 

Karolinska Development AB : Net sales amounted to 0.6 million Swedish crowns ($70,000) in Q2 (1.1 million crowns in Q2 2015) .Operational costs in Q2 amounted to 6.6 million crowns, a reduction of 46 pct compared to 12.2 million crowns in Q2 2015.  Full Article

Karolinska Development divests holding in Clanotech to Rosetta Capital
Tuesday, 5 Jul 2016 02:08am EDT 

Karolinska Development AB : Says KDev Investments, investment fund jointly owned by Karolinska Development and Rosetta Capital, will transfer all its shares in Clanotech to Rosetta Capital . Portfolio Net Fair Value will decrease by 54.8 million Swedish crowns ($6.49 million) .Retains an economic interest in company through an earn-out agreement.  Full Article

Karolinska Development: Lipidor and Cadila Pharmaceuticals agree on Phase III study and sale of Psoriasis product
Wednesday, 1 Jun 2016 02:00am EDT 

Karolinska Development AB : Lipidor and Cadila Pharmaceuticals announce agreement on Phase III clinical study and joint commercialization of topical Psoriasis product . Lipidor and Cadila Pharmaceuticals have entered into collaboration agreement on commercialization of sprayable anti-psoriatic product consisting of generic Vitamin D analogue, Calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, AKVANO . Product targets patients with mild to moderate psoriasis .Under collaboration agreement, Cadila Pharmaceuticals will conduct a Phase III program in India starting in 2016.  Full Article

Karolinska Development Q1 net sales fall to SEK 0.6 million
Tuesday, 10 May 2016 02:12am EDT 

Karolinska Development AB : Q1 net sales 0.6 million Swedish crowns ($75,000) versus 1 million crowns year ago .Q1 operating loss for Investment Entity 90.1 million crowns versus loss 241.8 million crowns year ago.  Full Article

Karolinska Development says portfolio company Aprea raises SEK 437 mln
Wednesday, 9 Mar 2016 02:00am EST 

Karolinska Development AB:Says its portfolio company Aprea raises 437 million Swedish crowns in a Series B financing round.‍Aprea is investigating APR-246 in phase Ib/II clinical study in high-grade serous ovarian cancer​‍.New funds will be used by Aprea to advance clinical development of its lead cancer program​.Company is planning to conduct exploratory trials in other cancer indications​.  Full Article

More From Around the Web

BRIEF-Karolinska Development: research collaboration with Memorial Sloan Kettering Cancer Center

* Karolinska Development company Aprea Therapeutics announces research collaboration with Memorial Sloan Kettering Cancer Center